Why Did Invitae Stock Fall 17% in July?
Invitae (NYSE: NVTA) shares dropped 17% in July as investors moved capital away from the smaller innovative genomic science stocks. No meaningful news was published about the stock, though there were announcements that other care providers would be partnering with Invitae to add genetic testing to their service selection.
Invitae is a relatively small and unprofitable company with massive growth aspirations. That attracts speculative investors, making the stock prone to substantial volatility. As the chart below shows, Invitae was quite active during a month without any important news. Its price movements were essentially more extreme versions of those exhibited by similar companies.
Source Fool.com
